Todd Matthew Kolb

Medicine & Life Sciences

1. Pulmonary Arterial Hypertension 100%
2. Pulmonary Hypertension 64%
3. Systemic Scleroderma 35%
4. Lung 28%
5. Right Ventricular Function 25%
6. Survival 21%
7. Xanthine Dehydrogenase 17%
8. Right Ventricular Dysfunction 16%
9. Hypoxia 14%
10. ambrisentan 13%
11. Heart Failure 12%
12. Tadalafil 11%
13. Vascular Resistance 11%
14. Endostatins 11%
15. Apoptosis 10%
16. Mortality 10%
17. Macrophage Migration-Inhibitory Factors 10%
18. Cardiac Catheterization 9%
19. Endothelial Cells 9%
20. Okadaic Acid 9%
21. Familial Primary Pulmonary Hypertension 8%
22. Caspase 3 8%
23. Hemodynamics 8%
24. Tuberous Sclerosis 2 7%
25. Magnetic Resonance Imaging 7%
26. Mitogen-Activated Protein Kinases 7%
27. Protein Kinases 7%
28. Stroke Volume 7%
29. Serum 7%
30. Smoke 7%
31. Pulmonary Artery 7%
32. Tobacco Products 7%
33. Magnetic Resonance Spectroscopy 7%
34. Lung Compliance 7%
35. Schnitzler Syndrome 7%
36. Heart Ventricles 6%
37. Catheters 6%
38. Semaxinib 6%
39. Exercise 6%
40. Febuxostat 6%
41. Pulmonary Wedge Pressure 6%
42. MAP Kinase Kinase Kinase 5 6%
43. Vascular Endothelial Growth Factor Receptor-1 5%
44. Pressure 5%
45. Capillary Permeability 5%
46. Therapeutics 5%
47. Cyclic GMP-Dependent Protein Kinases 5%
48. Tuberous Sclerosis 5%
49. Ventricular Remodeling 5%
50. Angiopoietins 5%